NASHVILLE, Tenn. (March 1, 2017) – Healthcare information technology firm NextGxDx Inc. has announced that it is now Concert Genetics. The change is intended to reflect the company’s mission of providing data-driven tools to connect, unify and simplify the world of genetic testing for stakeholders across the healthcare system – including hospitals and health systems, clinicians, health plans, labs and governing organizations.
“Our business, like the broader genetic testing industry, has grown and evolved significantly since I founded the company,” said Mark Harris, Ph.D., chief innovation officer of Concert Genetics. “Initially we focused exclusively on building a solution to connect genetic testing laboratories and clinicians, transforming the process of identifying, comparing and ordering genetic tests. Today our reach and mission is much greater, and we are proud to announce a new name that represents our work, culture, and where we’re headed as a company.”
“Precision medicine is the most exciting frontier in healthcare,” said Rob Metcalf, CEO of Concert Genetics. “But the complexity and rapid expansion of genetic testing and related treatments is challenging stakeholders across the healthcare system to capture and share the data necessary to prove the clinical value of precision medicine, justify the significant investment in it, and make it an established part of medical practice. We are a catalyst for connecting the disparate genetic health stakeholders so everyone can work together – in concert – to unlock the full potential of genetic testing for delivering effective, personalized treatments.”
Formed in 2010, Concert Genetics provides a suite of tools to support transparency and efficiency in genetic testing among hospitals and health systems, clinicians, health plans, labs and governing organizations. For example, Concert Genetics hosts the most comprehensive and accurate searchable database of genetic tests, available at no charge to clinicians who are searching for the right test for their patients. GeneConnect, the company’s genetic test utilization management tool for hospitals, is used by leading children’s hospitals and academic medical centers across the country. Concert for Health Plans (formerly GenePayer™) provides health insurers with market intelligence on genetics to inform policy development and bring transparency to reimbursement.
Concert Genetics will continue to support these products and services while expanding its role fostering collaboration among genetic health stakeholders in order to facilitate the delivery of precision medicine.
To learn more about Concert Genetics, visit the company’s website at www.ConcertGenetics.com.
About Concert Genetics
Concert Genetics provides software and analytic tools to connect, simplify and unify the world of genetic testing for hospital and health systems, clinicians, health plans, labs and governing organizations. Concert’s unique applications are built on a market-leading database that combines its index of the entire U.S.-based clinical genetic testing market – today more than 65,000 testing products – with other enriched data, such as genetic testing claims data from more than 100 million insured members. This data powers the leading genetic test search tool, specialized industry benchmarking and nuanced analysis of market dynamics. Concert aims to connect the disparate stakeholders in the healthcare community to help unlock the full potential of genetic testing for delivering precision medicine. Learn more at www.ConcertGenetics.com.
# # #
Media Contact:
Erin George
615-946-9914
erin@lovell.com